Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that the Israel Innovation Authority (IIA) has approved an expanded grant for its project to develop a robotic aseptic fill & finish platform. The company can now utilize the full approved grant budget of NIS 5 million over two years, with approximately 66% of the funding being non-dilutive. This support will enable Scinai to acquire and validate a fully automated robotic-arm aseptic fill & finish system that aligns with EU GMP Annex 1 standards, with validation targeted for the third quarter of 2026.
The investment is part of Scinai's broader CDMO expansion strategy, following its acquisition of Recipharm Israel Ltd. and a commercial collaboration with Recipharm. The robotic aseptic fill & finish platform will strengthen Scinai's integrated two-site manufacturing platform and enhance its sterile biologics capabilities. By maximizing non-dilutive funding, the company maintains disciplined capital allocation while advancing its technological infrastructure.
Scinai operates as a biopharmaceutical company with a contract development and manufacturing organization (CDMO) and a focused immunology R&D pipeline. The CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies, operating two sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne. The CDMO supports external clients from preclinical development through Phase I/II clinical supply, including biologics process development, analytical method development, sterile fill and finish, clinical cGMP manufacturing, and small-molecule API process development and optimization.
Through a strategic commercial collaboration agreement with Recipharm, Scinai offers clients a pathway from early clinical development to late-stage and commercial manufacturing within Recipharm's global network. This structure enables continuity of development, streamlined tech transfer, and reduced scale-up risk. The CDMO unit primarily engages with early-stage and emerging biotech companies and mid-size pharmaceutical companies outsourcing early development programs.
In parallel, Scinai is advancing a focused immunology pipeline through its R&D unit, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The company is seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation.
For more details, the full press release is available at https://ibn.fm/SxadB. The latest news and updates relating to SCNI can be found in the company's newsroom at https://ibn.fm/SCNI.
